These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29727613)

  • 1. Therapeutic potential of patupilone in epithelial ovarian cancer and future directions.
    Rogalska A; Marczak A
    Life Sci; 2018 Jul; 205():38-44. PubMed ID: 29727613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epothilones in the treatment of ovarian cancer.
    Diaz-Padilla I; Oza AM
    Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
    Fumoleau P; Coudert B; Isambert N; Ferrant E
    Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical applications of epothilones: a review of phase II studies.
    Larkin JM; Kaye SB
    Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
    Andreopoulou E; Muggia F
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of the epothilones : a novel class of antineoplastic drugs.
    Reichenbach H; Höfle G
    Drugs R D; 2008; 9(1):1-10. PubMed ID: 18095749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B.
    Rogalska A; Szula E; Gajek A; Marczak A; Jóźwiak Z
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):600-610. PubMed ID: 23838010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells.
    Rogalska A; Gajek A; Marczak A
    Phytomedicine; 2019 Aug; 61():152847. PubMed ID: 31029905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patupilone in cancer treatment.
    Bystricky B; Chau I
    Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [TUBB3 role in the response of tumor cells to epothilones and taxanes].
    Marczak A; Rogalska A
    Postepy Hig Med Dosw (Online); 2015 Jan; 69():158-64. PubMed ID: 25661915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.